REMARKS

Applicants respectfully request that the Specification at page 1, before line 1, be amended as detailed above, to correct an obvious error. In this regard, upon review of the cross-reference, it was noticed that the filing date for prior copending application Serial No. 09/913,106, now issued U.S. Patent No. 6,642,233, was incorrectly cited in a Preliminary Amendment filed on September 16, 2003. Enclosed is the cover page for US Patent No. 6,642,233, as support for the instant amendment, as it properly indicates that the §371(c)(1), (2), (4) date of said application is August 9, 2001, and not April 9, 2001. No new matter has been added.

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982 in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

Dated: April 29, 2005

Julie Anne Knight, Registration No. 48,867
Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3679
Telefax: 908-231-2626

Docket No. IVD1118 US DIV

Enclosure

US006642233B1

(12) **United States Patent**
Ducoux et al.

(10) **Patent No.: US 6,642,233 B1**
(45) **Date of Patent: Nov. 4, 2003**

(54) **1-PHENACYL-3-PHENYL-3-(PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM**

(75) Inventors: **Jean-Philippe Ducoux**, Combaillaux (FR); **Xavier Emonds-Alt**, Combaillaux (FR); **Patrick Guenle**, Teyran (FR); **Vincenzo Proietto**, Saint Georges D'Orques (FR)

(73) Assignee: **Sanofi-Synthelabo**, Paris (FR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/913,106**

(22) PCT Filed: **Feb. 8, 2000**

(86) PCT No.: **PCT/FR00/00284**

§ 371 (c)(1),
(2), (4) Date: **Aug. 9, 2001**

(87) PCT Pub. No.: **WO00/47572**

PCT Pub. Date: **Aug. 17, 2000**

(30) **Foreign Application Priority Data**

Feb. 10, 1999 (FR) 99 01593
Apr. 7, 1999 (FR) 99 04429

(51) **Int. Cl.**[7] **A61K 31/535**; A61K 31/445; C07D 211/14; C07D 413/14

(52) **U.S. Cl.** 514/235.5; 514/326; 514/227; 514/316; 546/186; 546/189; 546/209; 544/106; 544/129

(58) **Field of Search** 546/186, 187, 546/189, 209; 544/106, 129; 540/596; 514/315, 316, 326, 227, 235.5

(56) References Cited

U.S. PATENT DOCUMENTS

5,340,822 A * 8/1994 Emonds-Alt et al. 514/316
5,770,735 A 6/1998 Emonds-Alt et al.

FOREIGN PATENT DOCUMENTS

EP 0 512 901 11/1992
EP 0 714 891 6/1996
WO 96/06094 2/1996

* cited by examiner

Primary Examiner—Rita Desai
(74) *Attorney, Agent, or Firm*—Paul E. DuPont; Michael D. Alexander

(57) **ABSTRACT**

The invention relates to the compounds of formula:

(I)



as well as to the salts thereof with inorganic or organic acids, to solvates thereof and/or to hydrates thereof, which have strong affinity and high selectivity for the human NK_1 receptors of substance P.

The invention also relates to the process for preparing them, to the intermediate compounds of formula (VII) which are useful for the preparation, to pharmaceutical compositions containing them and to their fuse for the manufacture of medicinal products intended for treating any pathology in which substance P and the human NK_1 receptors are involved.

15 Claims, No Drawings